Vivos Therapeutics, INC 10-Q quarterly reports

Vivos Therapeutics reports Q1 2026 revenue of $5.1 million, driven by its new medical-provider focused business model, while facing ongoing liquidity and Nasdaq compliance challenges.

Vivos Therapeutics, Inc. reported a significant increase in net losses and a going concern warning despite revenue growth driven by its new acquisition-focused business model.

Vivos Therapeutics, Inc. reported increased net losses and a significant cash burn for the first half of 2025, despite a strategic pivot towards acquiring and managing sleep treatment centers.

Vivos Therapeutics' Q1 2025 revenue decreased by 12% year-over-year as the company transitions its business model towards strategic alliances and acquisitions of sleep centers.

Vivos Therapeutics saw a revenue increase in Q3 2024, driven by product sales and a strategic shift towards alliances with sleep centers.

Vivos Therapeutics, Inc. reports a $7.5 million private placement and a strategic shift towards alliances with sleep centers, alongside its Q2 2024 financial results.

Vivos Therapeutics experienced a decrease in revenue and a net loss in the first quarter of 2024, while also navigating strategic shifts and ongoing market challenges.